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Abstract
 
By analyzing T cell responses against foreign major histocompatibility complex (MHC) mole-
cules loaded with peptide libraries and defined self- and viral peptides, we demonstrate a pro-
found influence of self-MHC molecules on the repertoire of alloreactive T cells: the closer the
foreign MHC molecule is related to the T cell’s MHC, the higher is the proportion of peptide-
specific, alloreactive (“allorestricted”) T cells versus T cells recognizing the foreign MHC mol-
ecule without regard to the peptide in the groove. Thus, the peptide repertoire of alloreactive
T cells must be influenced by self-MHC molecules during positive or negative thymic selec-
tion or peripheral survival, much like the repertoire of the self-restricted T cells. In conse-
quence, allorestricted, peptide-specific T cells (that are of interest for clinical applications) are
easier to obtain if T cells and target cells express related MHC molecules.
Key words: peptide library • T cell repertoire • molecular basis of alloreactivity • limiting 
dilution • positive selection
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Introduction
 
Alloreactive T lymphocytes respond to allelic MHC vari-
ants in the apparent absence of nominal antigen and are the
cause for important clinical problems such as graft rejection
and graft versus host disease. In vitro, alloreactive T cells
are activated easily by foreign MHC molecules without
previous in vivo priming and are detectable in amazingly
high frequencies (1). The molecular basis for these phe-
nomena has not been elucidated, despite extensive charac-
terization of peptide requirements in alloreactivity and the
solution of several molecular structures of the 2C and
AHIII12.2 TCR allo- and xenomodels (2–5).
Several hypotheses have been proposed to explain allore-
activity (2). Matzinger and Bevan (6) suggested that allore-
active T cells recognize many different cellular antigens,
e.g., peptides, together with the foreign MHC. This model
explains the strong alloresponse by multiple binary interac-
tions between allorestricted T cell clones and new peptides
not presented by self-MHC. Later, Kaye and Janeway (7)
and Bevan (8) proposed that alloreactive T cells see all cell
surface MHC molecules regardless of peptides as antigens,
leading to a high determinant density per target cell. In the
meantime, evidence for peptide-dependent and peptide-
independent allorecognition has accumulated. On the one
hand, for several alloreactive T cell clones the exact pep-
tides recognized, which can be present at both high and
low copy numbers, have been identified (9–13). On the
other hand, recognition of MHC molecules in the absence
of peptides has been clearly demonstrated (14, 15). There
are also cases where the peptide changes structural charac-
teristics of the MHC molecule and leads to recognition by
certain T cell clones in a peptide-dependent rather than
peptide-specific manner (16–18). Today, the two models
of allorecognition may be seen as two extremes on a scale
where MHC and peptide contribute in different degrees to
the overall binding energy between the TCR and its
ligand. Accordingly, Daniel et al. explained the decreased
peptide specificity of the alloreactive T cell clone 2.102
 
with certain allelic 
 
a
 
-helical residues of the foreign MHC,
which supposedly supply more binding energy to the TCR
than the respective self-MHC molecule (19).
The involvement of peptides in alloreactivity that are
present on stimulator cells in low copy numbers (3, 13)
raised the possibility of generating allorestricted CTLs
against tumor-associated self-peptides (self as seen from the
tumor’s host) presented by MHC molecules (nonself for
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the T cells) for adoptive immunotherapy (20–22). For this
purpose, referring to allogeneic repertoires is necessary be-
cause T cell tolerance is MHC restricted (20, 23–25). Stauss
and colleagues and our group demonstrated high avidity al-
lorestricted CTLs against tumor-associated peptides and li-
braries from allogeneic mouse and human repertoires (21,
26–28). However, a T cell repertoire, which contains T
cells recognizing peptides bound to nonself-MHC mole-
cules with high avidity contradicts the well-established bias
of T cells to react against antigens preferentially in the con-
text of self-MHC (29).
To analyze the peptide repertoire of alloreactive T cells
and the potential influence of self-MHC molecules, we
stimulated naive splenic T cells of MHC class I mutant or
H2 recombinant mice against RMA-S cells (H2
 
b
 
) loaded
with defined K
 
b
 
- or D
 
b
 
-specific peptide libraries (K
 
b
 
L, D
 
b
 
L)
 
1
 
under limiting dilution conditions. The relative frequencies
of peptide-specific versus peptide-nonspecific T cells were
determined, and several T cells of interesting peptide speci-
ficity were expanded and further analyzed. The results allow
an unexpected insight into the relations between self-MHC
and the repertoire of alloreactive T cells.
 
Materials and Methods
 
Mice, Cell Lines, and Virus.
 
C57BL/6 (abbreviated B6) and
BALB/c mice were purchased from Charles River. B10.A(5R)
(5R), B10.HTG (HTG), and B6.C-H2
 
bm1
 
 (bm1) animals were
obtained from The Jackson Laboratory and maintained in our an-
imal facility. B6.C-H2
 
bm13 
 
(bm13) and B6.C-H2
 
bm14
 
 (bm14) mice
were received from Drs. R. Brandt and C.J.M. Melief (Leiden
University Medical Center, The Netherlands). FVB/N trans-
porter associated with antigen processing 1
 
2
 
/
 
2 
 
(TAP)-1
 
2
 
/
 
2
 
 [30])
mice were obtained from Drs. H. ter Rile and A. Berns (Cancer
Institute, Amsterdam, The Netherlands) and also bred in our ani-
mal facility. EL4, RMA (H2
 
b
 
, TAP
 
1
 
), and RMA.S (H2
 
b
 
, TAP
 
2
 
)
cell lines were maintained in RPMI 1640 (Sigma Chemical Co.)
supplemented with 2 mM 
 
l
 
-glutamine (BioWhittaker), 2 
 
m
 
M
2-ME, and 10% FCS (Sigma Chemical Co.). For generating blasts,
0.5–2 
 
3
 
 10
 
7 
 
splenocytes (in 5–10 ml RPMI) were stimulated for
2 d with 2.5–5 
 
m
 
g/ml Con A (Boehringer Mannheim), replated
in CTL medium (see below), and used on days 3–5 of culture.
Vesicular stomatitis virus (VSV) was obtained from Dr. R. Za-
watzky (German Cancer Research Center, Heidelberg, Ger-
many).
 
Peptides.
 
Peptides and libraries were synthesized and analyzed
as described (27). The K
 
b
 
L has been described previously (27),
and the D
 
b
 
L consisted of the amino acids indicated in Table I (an-
chor positions in bold). Both libraries bind to the respective
MHC allele as strongly as control peptides from OVA and influ-
enza nucleoprotein in an RMA.S induction assay (data not
shown). The new H2-K
 
b
 
 ligands were identified as described
previously (31) by immunoprecipitation of peptide–MHC com-
plexes, treatment with 0.1% trifluoric acid, ultrafiltration, frac-
tionation by HPLC, and subsequent analysis by automated Ed-
 
man degradation (sequencer model Procise 494A; Applied Bio-
systems).
 
Generation of Effector Cells and CTL Assays.
 
Splenocytes were
plated in limiting dilution in round-bottomed 96-well plates
(Greiner), starting with 1–2 
 
3 
 
10
 
5
 
 cells/well and diluting 1:2.
Each well received 5 
 
3
 
 10
 
5
 
 irradiated (33 Gy) stimulators in 200
 
m
 
l of 
 
a
 
-MEM (GIBCO BRL) with the above-listed supple-
ments, including 5% Con A–induced rat splenocyte supernatant,
50 
 
m
 
M 
 
a
 
-methylmannoside (CTL medium; Roth), and, where
applicable, a peptide library (500 ng/ml) or a peptide mixture.
After 7 d, the cultures were stimulated as before with peptides at
50 ng/ml. The cultures were tested 4–6 d later in a split-well
 
51
 
Cr-release assay, as described previously (27). For expansion,
CTLs were restimulated in 48- and 24-well plates with 250 or
5 
 
3
 
 10
 
5
 
 irradiated TAP-1
 
2
 
/
 
2
 
 splenocytes, respectively.
 
Results
 
Differential Requirement for Synthetic Peptides in Alloreactivity.
 
For the generation of tumor-specific CTLs, the holes in the
self-restricted T cell repertoire led us to raise CTLs against
peptide libraries presented on MHC molecules foreign to
the T cells (27, 28). In the course of such experiments, we
noticed difficulties in raising H2-K
 
b
 
– or H2-D
 
b
 
–restricted
CTLs from H2
 
d
 
 and H2
 
k
 
 animals against several individual
peptides (data not shown) and investigated the influence of
the responder’s haplotype.
Splenocytes from HTG, bm1, and B6 mice were stimu-
lated with TAP-1
 
2
 
/
 
2
 
 (H2
 
b
 
) splenocytes in the presence of
an H2 K
 
b
 
L under limiting dilution conditions. HTG ani-
mals express the K
 
d
 
 allele with 35 polymorphic amino acids
within the 
 
a
 
1 and 
 
a
 
2 domains, whereas the K
 
bm1
 
 allele car-
ries merely 3 amino acid exchanges, both compared with
K
 
b
 
 (Table II). After one restimulation, the cultures were
tested against TAP
 
2
 
 RMA.S cells (H2
 
b
 
) in the presence or
absence of K
 
b
 
L. H2 expression was not increased under our
experimental conditions (data not shown). The library is a
strong antigen for B6 responders, as it contains numerous
nonself-peptides (Fig. 1, top right). Previously, we have
shown that such CTLs can be of high avidity towards the
particular peptide or peptides recognized (27). For the allo-
geneic responders, it turned out that the HTG splenocytes
generated less allorestricted, i.e., K
 
b
 
-restricted, and peptide-
specific/dependent cultures (ratio of peptide-specific [P] to
structure-specific [S] cultures 1:4) than bm1 splenocytes
(P/S 
 
5 
 
1:1; Fig. 1, top). These results suggest that the bm1
repertoire is more prone to react in a peptide-dependent
 
1
 
Abbreviations used in this paper:
 
 B6, C57BL/6; K
 
b
 
L or D
 
b
 
L, K
 
b
 
 or D
 
b
 
 bind-
ing peptide library, respectively; K
 
b
(self)
 
, mixture of 10 K
 
b
 
 binding self-
peptides; TAP, transporter associated with antigen processing; VSV, ve-
sicular stomatitis virus.
 
Table I.
 
H2-D
 
b
 
 Binding Peptide Library D
 
b
 
L (n 
 
5
 
 2,000)
 
123456789
FQND
 
N
 
GYT
 
M
 
IA V AV
NM Q L T
SS K M Q
AEE 
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way towards K
 
b
 
 than the HTG repertoire. Out of the 35
amino acids polymorphic between K
 
d
 
 and K
 
b
 
, 13 make
contact with the bound peptide (32, 33), whereas 2 (resi-
dues 79 and 155) are bound by the 2C TCR directly (34).
However, one of the three amino acids that are polymor-
phic between K
 
b
 
 and K
 
bm1
 
 contacts the 2C TCR directly
(residue 155; Table II). It is tempting to speculate that this
residue is responsible for the finding that about half of the
cultures recognize RMA.S cells in the absence of K
 
b
 
L.
These data show that allogeneic MHC molecules, which
carry amino acid exchanges at positions that are responsible
for peptide binding, preferentially elicit an alloresponse
against the bound peptides, as one would expect from con-
sidering the structure of the MHC–peptide complex.
 
None of the polymorphic amino acids of H2-D
 
bm13
 
 and
H2-D
 
bm14
 
 (compared with D
 
b
 
) are directly involved in
TCR contacts (Table II). Consequently, after stimulation
of splenocytes with TAP-1
 
2
 
/
 
2
 
 cells and a D
 
b
 
L, the majority
of cytotoxicity was directed towards D
 
b
 
L-coated RMA.S
cells (Fig. 1, bottom). Amino acid 70, which is exchanged
in D
 
bm14
 
, is positioned at the inner rim of the 
 
a
 
1 helix and
seems to cause some structural change that is detected by
several cultures reacting to both D
 
b
 
L-coated and untreated
RMA.S cells (P/S 
 
5 
 
5:1). The contribution of cultures
specific for structural elements to overall alloreactivity is
even further reduced in the case of bm13 responders,
which carry polymorphic residues primarily determining
the chemical environment of the binding groove’s F
pocket (P/S 
 
5 
 
10:1). Our data indicate that increasing sim-
ilarity between 
 
a
 
-helical residues of the responder’s and the
stimulator’s MHC increases the contribution of peptide-
specific or -dependent T cells to an alloresponse.
 
Differential Requirement for Natural Peptides in Alloreactivity.
 
In the experiments described above, we made use of pep-
tide libraries of limited complexity to replace the more di-
verse set of self-peptides on TAP
 
1
 
 cells. Under our loading
conditions (1 h of peptide incubation at 37
 
8
 
C), no increase
in the expression of H2 molecules on RMA.S cells could
be detected. This was true both for incubation with the
peptide library and with individual peptides (data not
shown). We wondered whether the above observations
also apply to alloreactivity against cells expressing TAP, the
wild-type complement of peptides and, therefore, the natu-
ral density of class I molecules on the cell surface. BALB/c,
bm1, bm13, and bm14 splenocytes were stimulated with
B6 cells under limiting dilution conditions and tested against
RMA versus RMA.S target cells. In general, a higher pro-
portion of microcultures reacting with the foreign MHC
was detected irrespective of TAP expression (Fig. 2). This
result suggests that TAP
 
1
 
 cells could stimulate more T cells
specific for structural elements of K
 
b
 
 present on both TAP
 
1
 
and TAP
 
2
 
 cells, because they express a higher density of
 
Table II.
 
Mutation Position Exchanges
Pocket
(peptide res.) TCR interaction
K
 
bm1
 
152 Glu
 
®
 
Ala
D (3), C (6),
E (7) –
155 Arg
 
®
 
Tyr
D (3), C (6),
E (7) CDR1
 
a
 
, 2
 
a
 
, 3
 
b
 
156 Leu
 
®
 
Tyr
D (3), C (6),
E (7) –
D
 
bm13
 
114 Leu
 
®
 
Gln
D (3), C (6),
E (7), F (9/10) –
116 Phe
 
®
 
Tyr
C (6), E (7),
F (9/10) –
119 Glu
 
®
 
Asp
D
 
bm14
 
70 Gln
 
®
 
His
B (2), D (3),
C (6), F (9/10) –
Mutated MHC class I molecules of mouse strains used in this study. 
Compiled from references 34, 56–58.
Figure 1. The responder H2
haplotype influences the role of
peptide libraries in CTL allore-
activity. Splenocytes of the given
strains were plated in limiting di-
lution and stimulated with irradi-
ated TAP-12/2 (H2b) spleno-
cytes in the presence of KbL
(top) or DbL (bottom). The 96
cultures were assayed for CTL
activity against RMA.S cells 51Cr
labeled in the absence or pres-
ence of the respective library.
Numbers of cultures within the
arbitrarily chosen regions are in-
dicated to allow for better com-
parison. Spontaneous release was
,10%. The experiments were
repeated with similar results.808 Role of Peptides in Alloreactivity
Allorestricted CTLs against Defined Viral Peptides. To dem-
onstrate more clearly the exclusive specificity of allore-
stricted CTLs from a related strain, a line was generated
from bm1 against Kb and the immunodominant peptide
from VSV (pVSV). The CTL line B6E10 was specific for
pVSV, since it did not lyse RMA.S cells coated with the
OVA257–264 peptide (Fig. 4 a) or any other of 38 Kb
binding peptides tested (data not shown). The line also
does not cross-react with self-peptides presented by Kb,
since the TAP1 cell line EL4 was not recognized. In con-
trast, however, EL4 cells infected with VSV were lysed ef-
ficiently (Fig. 4 b). Thus we show, to our knowledge for
the first time, that allorestricted and highly specific CTLs
can be generated in vitro with synthetic peptides to lyse vi-
rus-infected targets.
Discussion
We have previously shown that Kb-restricted and pep-
tide-specific CTLs can be detected among BALB/c spleno-
cytes. Such cells were very rare and were obscured by many
alloreactive cells recognizing the target cells in a peptide-
independent manner. We had to deplete such cells in order
to generate several peptide-specific CTL lines (27). Similar
protocols have been successfully used to deplete graft-ver-
sus-host activity without compromising the graft-versus-
leukemia effect of allogeneic PBLs in bone marrow trans-
plantation (35–37). However, since we (data not shown)
and others (38) had difficulty generating allorestricted CTLs
against individual peptides when CTLs and target cells were
completely allogeneic to each other, we wished to analyze
the spectrum of CTL precursors specific for allogeneic
MHC–peptide complexes in closely related versus unrelated
MHC combinations. Our results show that an alloresponse
against a related MHC molecule contains more peptide-spe-
cific T cells than a response against an unrelated one: allore-
actions against an MHC molecule carrying groove mutations
only (bm13 anti-B6, bm14 anti-B6) were clearly dominated
by peptide-specific cells compared with a response against a
molecule with both groove and a-helical replacements (bm1
anti-B6). Among responses against molecules with several
groove and a-helical exchanges, peptide-specific cultures
were further reduced (HTG anti-B6, 5R anti-B6, BALB/c
anti-B6; Figs. 1 and 2). In addition, Kb-restricted CTLs from
bm1 against self- as well as viral peptides showed high speci-
ficity and efficiently recognized naturally presented peptides
(Figs. 3 and 4). We take these findings as evidence for an in-
creased contribution of molecular mimicry due to partial
identity to the alloresponse against similar MHC molecules,
as first suggested by Lechler et al. (39): the self haplotype de-
termines whether an alloresponse is dominated by cells rec-
ognizing nonself via multiple binary interactions or rather by
cells seeing the allelic MHC molecules regardless of bound
peptides. The mode of allorecognition, however, seems un-
related to the “antigenic strength,” as skin grafts done in the
mutant strain combinations used in our study are rejected in
a similar time frame (40, 41).
Figure 2. The responder H2 haplotype influences the role of endoge-
nous peptides in CTL alloreactivity. Splenocytes of the given strains were
stimulated under limiting dilution conditions with irradiated B6 spleno-
cytes. 192 cultures were assayed against RMA and RMA.S. Numbers of
cultures within the arbitrarily chosen areas are indicated to allow for bet-
ter comparison. Spontaneous release was ,21%.
H2 molecules on the cell surface. But again, bm1 responds
with more peptide-specific cultures (P/S 5 1:3) than the
completely allogeneic responder BALB/c (P/S 5 1:5), and
bm13 and bm14 respond with even more (P/S 5 3:1) than
bm1 (Fig. 2). These results extend our conclusion that the
particular responder–stimulator combination determines
the role of peptides to alloresponses among wild-type stim-
ulators and targets.
Allorestricted CTLs against Defined Self-Peptides. To fur-
ther characterize alloreactive CTLs raised from a responder
expressing an H2 molecule closely related to the stimulat-
ing one, we cultured bm1 splenocytes with irradiated
TAP-12/2 cells in the presence of 10 self-peptides eluted
from Kb (Kb
[self]) by us and other laboratories (Fig. 3, a and
b). Peptide-specific microcultures were expanded, and the
specific peptide recognized was determined. We detected
reactivities against determinants from the transcription fac-
tor Erk2, the cytosolic protein b-catenin, and the endothe-
lial pas domain protein (EPAS-1; Fig. 3 c) as well as from
RNA helicase p54 and the mouse mammary tumor virus
envelope protein (data not shown). The specificity of the
“aberrant” CTL lines recognizing RMA-S in the absence
but not presence of added peptides (see Fig. 3 b, right)
could not be elucidated. Importantly, all peptide-specific
CTL lines recognized RMA tumor cells as well as B6 Con
A blasts, but not bm1 Con A blasts, not even in the pres-
ence of peptides (Fig. 3 d). These results demonstrate that
allorestricted and peptide-specific CTLs can be generated
easily without depletion or extensive cloning from a related
mouse strain. The lines that were raised against synthetic
self-peptides can efficiently lyse target cells expressing phys-
iological levels of the self-antigen and thereby circumvent
peptide-specific self-tolerance.809 Obst et al.
The importance of the peptide-specific mode of alloreac-
tion was not obvious from structural information published
to date. Studies on molecules recognized by the 2C allo-
TCR (4, 34, 42, 43) and the xenoreactive clone AHIII12.2
(5, 44) do not explain the clones’ cross-reactivities by struc-
tural molecular mimicry. For 2C, only a critical negative
charge on the self-MHC–peptide complex has been mim-
icked by the allogeneic ligand, as suggested in reference 4.
We speculate that T cells responding to foreign MHC mol-
ecules carrying groove mutations interact with them in the
same way as T cells interacting with their respective self-
molecules. Such alloreactive T cells respond to the bound
peptides, as these peptides had not been present during neg-
ative selection. 
The T cell repertoire is shaped by selection events in the
thymus and the periphery (45–48). It is currently assumed
that a certain MHC haplotype selects 15–20% of CD41
CD81 thymocytes (49), of which 50% or more undergo
clonal deletion by bone marrow–derived APCs (50, 51).
Despite this profound imprint of the self-MHC on the T
cell repertoire, an influence of selection events on peptide
requirements of alloreactivity has not been shown. Our de-
tailed analysis of alloreactive cells on a population level now
Figure 3. Allorestricted CTL lines from bm1
mice against Kb binding self-peptides. (a) Self-pep-
tides eluted from Kb and used in this study as mix-
ture Kb
(self) (references 12, 43, 55, 59, 60; and this
study). (b) Splenocytes from bm1 animals were
plated in limiting dilution and stimulated with
TAP-12/2 cells in the presence of a mixture of self-
peptides at 500 (left), 100 (middle), and 50 ng/ml
(right). After 10 d, the cultures were assayed against
RMA.S in the absence or presence of the mixture.
Spontaneous release was ,10%. (c) Peptide speci-
ficity of expanded CTL lines. All peptides listed in a
were titrated on 51Cr-labeled RMA.S cells. The in-
dicated effector cells were added at effector to tar-
get ratios between 2 and 5. (d) The expanded CTL
lines recognize tumor cells and Con A–induced
blasts from B6, but not from bm1 mice. Spontane-
ous release was ,10% for tumor cells and ,18%
for blasts.
Figure 4. Allorestricted CTLs
can recognize VSV-infected cells.
(a) The bm1-derived CTL line
B6E10 raised against TAP-12/2
and the VSV-N52-59 peptide
(pVSV) lyses RMA.S cells after in-
cubation with the stimulating pep-
tide, but not with the OVA257–
264 peptide (pOVA). Effector to
target ratio was 2. (b) The same line
recognizes EL4 cells after infection
with 2 3 107 PFU VSV only.
Spontaneous release was ,20%.810 Role of Peptides in Alloreactivity
shows that allorecognition is readily influenced by the se-
lecting MHC molecule—rather than “hard-wired into the
TCR genes” (45, 52)—and mirrors the resemblance be-
tween self and foreign.
It is not clear whether negative or positive selection, pe-
ripheral survival, or all three are skewing the repertoire to-
wards peptide-specific/dependent recognition of related
MHC molecules. Favoring negative selection, one could
argue that, for example, the bm13 repertoire, due to its simi-
larity to B6, is simply purged of T cells reactive against struc-
tural determinants of Db and contains peptide-specific cells
only. However, negative selection may not completely ex-
plain the skewing, since the antigenic strength of the pocket
mutants bm13 and bm14 is almost as high as that of bm1,
which carries a polymorphic amino acid at a position in di-
rect contact with the TCR (40, 41). It is tempting to specu-
late that positive selection and peripheral survival enrich for
cells able to recognize similar MHC molecules in a peptide-
specific way and thereby modify the alloresponse as well.
The fact that tolerance is MHC restricted (20, 23–25) per-
mits the generation of high avidity CTLs against MHC–self-
peptide complexes for adoptive tumor therapy in three ways.
First, a responder’s T cell can react towards a peptide from its
own MHC groove if it is presented in a new context (same
groove, new a helices; references 3, 53, 54). Second, CTLs
have been raised against peptides presented by allogeneic
MHC molecules carrying several a-helical and groove mu-
tations (new groove, new helices; references 21, 27). Third,
alloreactive CTLs can recognize an MHC molecule with
groove mutations only because of the many new peptides it
carries, as in a self-restricted response (new groove, same he-
lices [reference 55, and this study]). We show here that the
latter possibility allows for the easy generation of allore-
stricted CTLs against defined self- and viral peptides. We
therefore suggest that this approach is more likely to yield
high avidity human CTLs against self- and other peptides,
including tumor-associated antigens. For example, to raise
HLA-A*0201–restricted CTLs, it may be useful to start with
T cells from a donor expressing A*0206 (1 mutation in
pocket B) rather than from a donor expressing, e.g., A*0301
(3 pocket mutations and 11 exchanges outside the groove). In
fact, 9 out of 22 HLA-A2 subtypes carry exclusively pocket
mutations relative to A*0201 (56). Which of these subtypes
is best suited to select T cells that respond to A*0201-bound
self-peptides remains to be determined.
Taken together, we have shown that self-MHC shapes
the repertoire not only of self-restricted, but also of alloreac-
tive T cells. A practical consequence of our data bears on the
generation of allorestricted, peptide-specific T cells, espe-
cially for those directed against tumor-associated peptides:
the success rate for getting such T cells should be higher if T
cell donor and stimulating APCs express MHC molecules
with similar a helices but different peptide binding grooves.
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